CD274 and colorectal carcinoma: Monoclonal antibodies against PD-1/PD-L1 have served in clinical treatment, and many studies show that mismatch repair-defective (dMMR)/microsatellite instability-high (MSI-H) CRC patients have a higher response rate to treatment with PD-1/PD-L1 inhibitors [12, 13].